Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride

Investigational New Drugs

Volumn 30, Issue 2, 2012, Pages 568-581

  Skelding, Kathryn A ^a   Barry, Richard D ^a   Shafren, Darren R ^a,b  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b Viralytics Ltd   (Australia)

Author keywords

Breast cancer; Colorectal cancer; Coxsackievirus A21; Doxorubicin hydrochloride; Oncolytic virus; Pancreatic cancer

Indexed keywords

CASPASE; DECAY ACCELERATING FACTOR; DOXORUBICIN; FLUOROURACIL; INTERCELLULAR ADHESION MOLECULE 1; ONCOLYTIC COXSACKIE VIRUS A21; ONCOLYTIC VIRUS; PACLITAXEL; TAMOXIFEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL SURVIVAL; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; COXSACKIE VIRUS; COXSACKIE VIRUS A21; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; ONCOLYTIC VIROTHERAPY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCID MOUSE; TUMOR XENOGRAFT; VIRUS REPLICATION; ADJUVANT CHEMOTHERAPY; ANIMAL; CELL CYCLE; CELL DEATH; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; ENTEROVIRUS; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; MOUSE; MOUSE MUTANT; NEOPLASM; PATHOGENICITY; PATHOLOGY; TIME; TUMOR CELL LINE; TUMOR VOLUME; VIROLOGY; VIRUS ENTRY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD55; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ENTEROVIRUS; FEMALE; FLOW CYTOMETRY; HUMANS; INJECTIONS, INTRAPERITONEAL; INTERCELLULAR ADHESION MOLECULE-1; MICE; MICE, SCID; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; TIME FACTORS; TUMOR BURDEN; VIRUS INTERNALIZATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861181816     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9614-0     Document Type: Article

References (36)

1. Parkin DM (2001) Global cancer statistics in the year 2000. Lancet Oncol 2(9):533-543
2. Greenberg PA, Hortobagyi GN, Smith TL et al (1996) Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14 (8):2197-2205
3. Fazal S, Saif MW (2007) Supportive and palliative care of pancreatic cancer. J Pancreas 8:240-253
4. Pecora AL, Rizvi N, Cohen GI et al (2002) Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 20(9):2251-2266
5. Hirasawa K, Nishikawa SG, Norman KL et al (2002) Oncolytic reovirus against ovarian and colon cancer. Cancer Res 62 (6):1696-1701
6. Stojdl DF, Lichty B, Knowles S et al (2000) Exploiting tumorspecific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6(7):821-825
7. Buckland FE, Bynoe ML, Tyrrell DA (1965) Experiments on the spread of colds. II. Studies in volunteers with Coxsackievirus A21. J Hyg (Lond) 63:327-343
8. Couch RB, Cate TR, Gerone PJ et al (1965) Production of illness with a small-particle aerosol of Coxsackie A21. J Clin Invest 44:535-542
9. Spickard A, Evans H, Knight V et al (1963) Acute respiratory disease in normal volunteers associated with Coxsackie A-21 viral infection. III. Response to nasopharyngeal and enteric inoculation. J Clin Invest 42:840-852
10. Shafren DR, Au GG, Nguyen T et al (2004) Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, Coxsackievirus A21. Clin Cancer Res 10(1 Pt 1):53-60
11. Au GG, Lindberg AM, Barry RD et al (2005) Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21. Int J Oncol 26(6):1471-1476
12. Berry LJ, Au GG, Barry RD et al (2008) Potent oncolytic activity of human enteroviruses against human prostate cancer. Prostate 68 (6):577-587
13. Skelding KA, Barry RD, Shafren DR (2009) Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21. Breast Cancer Res Treat 113:21-30
14. Au GG, Lincz LF, Enno A et al (2007) Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma. Br J Haematol 137:133-141
15. Garber K (2006) China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst 98:298-300
16. Sung C-K, Choi B, Wanna G et al (2008) Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma. Laryngoscope 118:237-242
17. Watanabe I, Kasuya H, Nomura N et al (2008) Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer. Cancer Chemother Pharmacol 61:875-882
18. Heise C, Lemmon M, Kirn D (2000) Efficacy with a replicationselective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration. Clin Cancer Res 6:4908-4914
19. Li Y, Yu DC, Chen Y et al (2001) A hepatocellular carcinomaspecific adenovirus variants, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res 61:6428-6436
20. Dias JD, Guse K, Nokisalmi P et al (2010) Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures. Eur J Cancer 46:625-635
21. Chahlavi A, Todo T, Martuza RL et al (1999) Replicationcompetent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1:162-169
22. Hoffmann D, Bayer W, Wildner O (2007) Local and distant immune-mediated control of colon cancer growth with fusogenic membrane glycoproteins in combination with viral oncolysis. Hum Gene Ther 18:435-450
23. Angelova AL, Aprahamian M, Grekova SP et al (2009) Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-IPV. Clin Cancer Res 15(2):511-519
24. Sei S, Mussio JK, Yang Q et al (2009) Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in nonsmall cell lung cancer cells. Mol Cancer 8:47
25. Shafren DR, Bates RC, Agrez MV et al (1995) Coxsackieviruses B1, B3, and B5 use decay accelerating factor as a receptor for cell attachment. J Virol 69(6):3873-3877
26. Coyne KE, Hall SE, Thompson S et al (1992) Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor. J Immunol 149 (9):2906-2913
27. Boyd AW, Wawryk SO, Burns GF et al (1988) Intercellular adhesion molecule 1 (ICAM-1) has a central role in cell-cell contact-mediated immune mechanisms. Proc Natl Acad Sci USA 85(9):3095-3099
28. Andersson P, Alm S, Edman K et al (2005) A novel and rapid method to quantify cytolytic replication of picornaviruses in cell culture. J Virol Methods 130:117-123
29. Ling YH, El-Naggar AK, Priebe W et al (1996) Cell cycledependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Mol Pharmacol 49:832-841
30. Piso P, Dahlke MH, Ghali N et al (2007) Multimodality treatment of peritoneal carcinomatosis from colorectal cancer: first results of a new German centre for peritoneal surface malignancies. Int J Colorectal Dis 22:1295-1300
31. Kouvaraki MA, Ajani JA, Hoff P et al (2004) Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22:4762-4771
32. Gurnani M, Lipari P, Dell J et al (1999) Adenovirus-mediated p53 therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer. Cancer Chemother Pharmacol 44:143-151
33. Kambara H, Saeki Y, Chiocca EA (2005) Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus. Cancer Res 65:11255-11258
34. Ichihara S, Yamada Y, Kawai Y et al (2007) Roles of oxidative stress and Akt signaling in doxorubicin cardiotoxicity. Biochem Biophys Res Commun 359:27-33
35. Palmieri FM, Perez EA (2003) Recent advances in adjuvant therapy for breast cancer. Semin Oncol Nurs 19:10-16
36. Aapro MS (2001) Adjuvant therapy of primary breast cancer: a review of key findings from the 7th international conference, St Gallen, February 2001. Oncologist 6:376-385